Article Text

Download PDFPDF
Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.
  1. H Humphreys,
  2. S Bourke,
  3. C Dooley,
  4. D McKenna,
  5. B Power,
  6. C T Keane,
  7. E C Sweeney,
  8. C O'Moráin
  1. Department of Clinical Microbiology, St James's Hospital, Dublin, Ireland.


    This study investigated the effect of colloidal bismuth subcitrate and cimetidine on Campylobacter pylori in peptic disease. In 74% of 135 patients with peptic disease diagnosed at endoscopy C pylori was detected before treatment. Compared with cimetidine, colloidal bismuth subcitrate significantly decreased the incidence of C pylori after six weeks of treatment (p less than 0.001). In the colloidal bismuth subcitrate group, subsequent healing of the lesion was correlated with the clearance of C pylori, unlike in the cimetidine group. C pylori was strongly associated with the presence of histological gastritis, which was decreased by colloidal bismuth subcitrate (p less than 0.001).

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.